A Phase 2 interventional study of Brentuximab vedotin and Placebo in Systemic Lupus Erythematosus, sponsored by Seagen Inc.. Terminated at 17 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-06-11.
Sponsored by Seagen Inc. (part of Pfizer) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 477 studies in Lupus Erythematosus, Systemic with a site in United States — 87 open to participants now, 127 under way, 28 of them phase 3. Lupus Erythematosus, Systemic · United States.
Among the 477 studies in Lupus Erythematosus, Systemic with a site in United States, this one is the 317th largest by enrollment of the 407 interventional ones that give a count, is one of 17 that started in 2015, is one of 120 in phase 2, and was the 205th registered.
1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.
Browse Lupus Erythematosus, Systemic studies →87 of the 477 studies in Lupus Erythematosus, Systemic with a site in United States are open now. Recruiting first, the newest first:
National Human Genome Research Institute (NHGRI) · Sites in United States, Peru
Ages 18–115
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) · Sites in United States
Ages 9–85 · Healthy volunteers
Stephan Grupp MD PhD · Sites in United States
Ages 8–25
EMD Serono Research & Development Institute, Inc. · Sites in United States
Ages 18–76
Fate Therapeutics · Sites in United States
Ages 18–70
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
477 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 130 · Phase 2 151 · Phase 3 75 · Phase 4 17
First in 1986; this study’s year is marked. 17 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 20 is below the median of 52 across 878 interventional studies indexed under Lupus Erythematosus, Systemic.
Median enrollment 70 across the 407 interventional studies, 223 across the 67 observational. Of the 309 that completed or were terminated, 147 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
264 of 477 have an industry lead sponsor. The 10 most frequent:
This study is registered under Seagen Inc., one of the names counted as Pfizer. Under that name alone:
Seagen Inc. is the lead sponsor of 88 studies on the registry; 1 is open to participants now.
Of its 27 completed or terminated interventional studies of FDA-regulated products, 14 (52%) have results posted.
Pfizer has 9 studies filed under Lupus Erythematosus, Systemic — fewer than ten, so there is no comparison to draw.
33 of the studies in Lupus Erythematosus, Systemic with a site in United States that are under way reach primary completion within a year, 7 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05672576Phase 3Viatris Innovation GmbHA Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus Erythematosus | 2026-12-31 |
| NCT05138133Phase 3AstraZenecaPhase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis | 2027-02-23 |
| NCT05843643Phase 3AbbVieProgram to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus | 2027-03 |
| NCT05639114Phase 3Novartis PharmaceuticalsPhase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1) | 2027-03-26 |
| NCT05648500Phase 3Viatris Innovation GmbHA Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus | 2027-03-31 |
Add all 33 to your calendar (.ics) → With an account.
Among the 477 studies in Lupus Erythematosus, Systemic with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety and tolerability of brentuximab vedotin in adults with active systemic lupus erythematosus (SLE).
Systemic lupus erythematosus (SLE) is a chronic, multisystem, disabling autoimmune condition, which predominantly affects women of childbearing years. Treatment options for SLE remain relatively limited. Regardless of the specific therapy chosen, the majority of patients continue to require long term immunomodulatory or cytotoxic therapy, resulting in long-term morbidity and mortality. Brentuximab vedotin is an antibody-drug conjugate (ADC) consisting of: 1) the chimeric immunoglobulin (Ig) G1 antibody cAC10, specific for human CD30, 2) the microtubule disrupting agent monomethyl auristatin E (MMAE), and 3) a protease-cleavable linker that covalently attaches MMAE to cAC10. Since CD30 and/or CD30-expressing immune cells may play significant key roles in the pathogenesis of SLE, brentuximab vedotin may be an efficacious therapy. This study intends to explore the potential for brentuximab vedotin as a therapy for SLE.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
4 dose groups
Drug: Brentuximab vedotin
Matching placebo
Drug: Placebo
Also known as: ADCETRIS (brentuximab vedotin)
Number and Percentage of Subjects Having an Adverse Event (AE)
Any treatment-emergent adverse events (TEAEs), any drug-related TEAEs, any SAEs, treatment-related serious adverse events (SAE), deaths, adverse events (AEs) leading to study discontinuation, and number of patients experiencing Grade 1, 2, and 3 TEAEs.
Time frame: Up to 127 days (9 weeks after final dose)
Proportion of Subjects Achieving an SRI Response at Day 85
Assessment for response was made using data only for the visit of interest (Day 85), without regard for changes at prior on-treatment visits. SRI: SLE Responder Index; SLE: Systemic lupus erythematosus
Time frame: 85 days
| Milestone | Placebo | Brentuximab Vedotin 0.3 mg/kg | Brentuximab Vedotin 0.6 mg/kg |
|---|---|---|---|
| Started | 4 | 8 | 8 |
| Completed | 4 | 7 | 7 |
| Not completed | 0 | 1 | 1 |
| Withdrew: Adverse event | 0 | 1 | 1 |
Any treatment-emergent adverse events (TEAEs), any drug-related TEAEs, any SAEs, treatment-related serious adverse events (SAE), deaths, adverse events (AEs) leading to study discontinuation, and number of patients experiencing Grade 1, 2, and 3 TEAEs.
| Participants | Placebo | Brentuximab Vedotin 0.3 mg/kg | Brentuximab Vedotin 0.6 mg/kg |
|---|---|---|---|
| Treatment-Emergent Adverse Event | 3 | 6 | 8 |
| Treatment-Related Adverse Event | 0 | 3 | 1 |
| Serious Adverse Event | 0 | 1 | 1 |
| Treatment-Related Serious Adverse Events | 0 | 1 | 0 |
| Deaths | 0 | 0 | 0 |
| Adverse Events Leading to Study Discontinuation | 0 | 1 | 1 |
| Any Grade 1 Adverse Event | 2 | 6 | 2 |
| Any Grade 2 Adverse Event | 2 | 4 | 7 |
| Any Grade 3 Adverse Event | 0 | 1 | 2 |
Assessment for response was made using data only for the visit of interest (Day 85), without regard for changes at prior on-treatment visits. SRI: SLE Responder Index; SLE: Systemic lupus erythematosus
| Participants | Placebo | Brentuximab Vedotin 0.3 mg/kg | Brentuximab Vedotin 0.6 mg/kg |
|---|---|---|---|
| Proportion of Subjects Achieving an SRI Response at Day 85 | 0 | 1 | 2 |
Collected over Up to 127 days (9 weeks after last dose). The safety reporting period for all AEs and SAEs is from the date of consent through the follow-up visit. All SAEs that occur after the safety reporting period and are considered study treatment-related in the opinion of the Investigator should also be reported to the Sponsor. Additionally, new-onset neuropathy, suspected PML, or other AEs/SAEs of interest are reported until the end of the follow-up period.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/4 (0%) | 0/4 (0%) | 3/4 (75%) |
| Brentuximab Vedotin 0.3 mg/kg | 0/8 (0%) | 1/8 (12.5%) | 6/8 (75%) |
| Brentuximab Vedotin 0.6 mg/kg | 0/8 (0%) | 1/8 (12.5%) | 8/8 (100%) |
| Event | Placebo | Brentuximab Vedotin 0.3 mg/kg | Brentuximab Vedotin 0.6 mg/kg |
|---|---|---|---|
| ConcussionInjury, poisoning and procedural complications | 0/4 | 0/8 | 1/8 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/4 | 1/8 | 0/8 |
| Event | Placebo | Brentuximab Vedotin 0.3 mg/kg | Brentuximab Vedotin 0.6 mg/kg |
|---|---|---|---|
| DizzinessNervous system disorders | 0/4 | 3/8 | 0/8 |
| NauseaGastrointestinal disorders | 0/4 | 2/8 | 0/8 |
| MalaiseGeneral disorders | 1/4 | 0/8 | 0/8 |
| Flank PainMusculoskeletal and connective tissue disorders | 1/4 | 0/8 | 1/8 |
| ArthritisMusculoskeletal and connective tissue disorders | 1/4 | 0/8 | 0/8 |
| Limb DiscomfortMusculoskeletal and connective tissue disorders | 1/4 | 0/8 | 0/8 |
| DepressionPsychiatric disorders | 1/4 | 0/8 | 0/8 |
| AlopeciaSkin and subcutaneous tissue disorders | 1/4 | 0/8 | 1/8 |
| Dermal CystSkin and subcutaneous tissue disorders | 1/4 | 0/8 | 0/8 |
| UrticariaSkin and subcutaneous tissue disorders | 1/4 | 0/8 | 0/8 |
| Age, Continuous(years) | Placebo | Brentuximab Vedotin 0.3 mg/kg | Brentuximab Vedotin 0.6 mg/kg | Total |
|---|---|---|---|---|
| Mean | 45.5 ± 8.66 | 50.8 ± 14.06 | 45.0 ± 11.20 | 47.4 ± 11.78 |
| Sex: Female, Male(Participants) | Placebo | Brentuximab Vedotin 0.3 mg/kg | Brentuximab Vedotin 0.6 mg/kg | Total |
|---|---|---|---|---|
| Female | 4 | 8 | 8 | 20 |
| Male | 0 | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | Brentuximab Vedotin 0.3 mg/kg | Brentuximab Vedotin 0.6 mg/kg | Total |
|---|---|---|---|---|
| Hispanic or Latino | 1 | 0 | 3 | 4 |
| Not Hispanic or Latino | 3 | 8 | 5 | 16 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Placebo | Brentuximab Vedotin 0.3 mg/kg | Brentuximab Vedotin 0.6 mg/kg | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 0 | 1 |
| Asian | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 1 | 5 | 7 |
| White | 3 | 6 | 3 | 12 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Placebo | Brentuximab Vedotin 0.3 mg/kg | Brentuximab Vedotin 0.6 mg/kg | Total |
|---|---|---|---|---|
| United States | 4 | 8 | 8 | 20 |
PDFs hosted by the registry, ClinicalTrials.gov.
The record gives a start of Jul 2015, a primary completion of Jun 2017 and a completion of Jun 2017. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2018, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in May 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Brentuximab Vedotin
Lupus Erythematosus, Systemic →